Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin

Abstract

The most effective regimen for patients with acute myeloid leukemia (AML) who do not achieve complete remission (CR) after one course of cytarabine and an anthracycline has not been extensively studied. We evaluated retrospectively the efficacy, toxicity, and prognostic factors for the achievement of CR following mitoxantrone and etoposide in 74 patients with newly diagnosed AML who did not respond to one course of therapy with cytarabine and idarubicin. CR was achieved in 39% of patients; 14% died of infectious complications; no grade 3 or 4 hepatic toxicities were observed. Median duration of overall survival was 9.0 months (95% CI 5.8-14.9 months). The median duration of relapse-free survival was 11.0 months (95% CI: 9.0-19.3 months). A lower CR rate was associated with unfavorable risk status at diagnosis and higher percent blasts. Our data suggest that the combination of etoposide and mitoxantrone is an effective second-course therapy in patients with newly diagnosed AML.

Acute Erythroleukemia in a Trauma Patient. A Case Report.

“…the treatment is with chemotherapy cytarabines (ara c) the regimen for induction therapy is the "7 + 3" regimen: cytarabine at 100 mg/m2/d intravenously (IV) by continuous infusion on days 1-7 plus an anthracycline (idarubicin 12 mg/m2 or commonly used daunorubicin 45-60 mg/ m2) or anthracene Dione (mitoxantrone 12 mg/ m2) (IV) push on days 1-3. [14,15] the regimen for consolidation therapy includes 2 options. the high-dose ara-c (HiDac) regimen includes cytarabine at 3 g/m2 IV q12h on days 1, 3, and 5 for 4 cycles.…”